Michael G Fehlings, PhD, MD, FACS, FRCSC

Follow Dr. Fehlings:
  1. Neuroprotection of the injured spinal cord
  2. Regenerative medicine for spinal cord injury (SCI) using stem cell and tissue engineering approaches
  3. Mechanisms of glial-axonal signalling using electrophysiological and imaging approaches
  4. Spinal cord and brain repair with a focus on Cerebral Palsy
  5. Developing and characterizing animal models of cervical spondylotic myelopathy (CSM), the most common cause of spinal cord dysfunction, and examining strategies for improving outcomes in this condition
  6. Clinical trials bringing lab-tested therapeutics to clinic
Our laboratory integrates molecular, imaging, electrophysiological and neurobehavioural approaches to examine the pathophysiology and treatment of central nervous system injury, using spinal cord injury as a model system. Current studies in SCI are focused on understanding the mechanisms of the secondary injury after SCI with a focus on examining the role of inflammation, development of novel neuroprotective strategies and the use of stem cell transplantation strategies to repair the spinal cord. The translation from benchside to bedside is a key goal of our research and is exemplified in the team's involvement in clinical trials.

Our laboratory plays a leading role in SCI-NET (Spinal Cord Injury New Emerging Team)--a unique, interdisciplinary team of clinicians and scientists with expertise in micro-neurosurgery and neurotrauma (Fehlings and Tator, UHN), stem cell and growth factor biology (van der Kooy, Nagy and Morshead, University of Toronto), tissue engineering and nanotechnology (Shoichet, University of Toronto).

SCI-NET is examining three integrated strategies to treat SCI:

  1. Application of experimental models of cervical SCI for regenerative therapeutics
  2. Determine the efficacy of exogenous stem cell mediated recovery following cervical SCI 
  3. Determine the efficacy of pharmacologically stimulated endogenous stem cell mediated recovery following cervical SCI
  4. Explore combinatorial treatments for cervical SCI involving chABC and endogenous/exogenous cells
The SCI-NET team is a key part of the regenerative medicine program at the McLaughlin Center for Molecular Medicine which provides an excellent, collaborative research environment.

A more recent area of research is a forward and reverse translation investigation of therapies for Cerebral Palsy. In this study, the focus is on more fully understanding the underlying mechanisms of constraint induced movement therapy (CIMT), which is already in use in the clinic, in order to optimize timing and duration. In addition, the team will study stem cell therapies as a means of augmenting therapies already in use.

Finally, Dr. Fehlings is involved with several clinical trials:

  1. Examining the use of Riluzole in cervical spondylotic myelopathy (CSM), a common spinal condition
  2. Examining the use of Riluzole in spinal cord injury (RISCIS)
  3. Approaches for the treatment of metastatic epidural spinal cord compression and CSM
  4. Surgical Timing in Acute Spinal Cord Injury Study (STASCIS) (published)
  5. Transplantation of stem cells for spinal cord injury
Global Spine J. 2019 Feb;9(1):85-103
Tetreault L, Nakashima H, Kato S, Kryshtalskyj M, Nagoshi N, Nouri A, Singh A, Fehlings MG
Global Spine J. 2019 Feb;9(1):18-24
Bateman AH, Larouche J, Goldstein CL, Sciubba DM, Choma TJ, Lawrence B, Cheng J, Fehlings MG, Paquette SJ, Yee AJM
World Neurosurg. 2019 Feb 08;:
Guha D, Jakubovic R, Alotaibi NM, Klostranec JM, Saini S, Deorajh R, Gupta S, Fehlings MG, Mainprize TG, Yee A, Yang VXD
eNeuro. 2018 Sep-Oct;5(5):
Rumajogee P, Altamentova S, Li L, Li J, Wang J, Kuurstra A, Khazaei M, Beldick S, Menon RS, van der Kooy D, Fehlings MG
Can J Neurol Sci. 2019 Jan;46(1):87-95
Guha D, Moghaddamjou A, Jiwani ZH, Alotaibi NM, Fehlings MG, Mainprize TG, Yee A, Yang VXD
Methods Mol Biol. 2019;1919:25-41
Khazaei M, Ahuja CS, Rodgers CE, Chan P, Fehlings MG
J Neurosurg Spine. 2018 Dec 20;30(1):1-18
Badhiwala JH, Ahuja CS, Fehlings MG
Eur J Cancer. 2018 Dec 06;107:28-36
Choi D, Pavlou M, Omar R, Arts M, Balabaud L, Buchowski JM, Bunger C, Chung CK, Coppes MH, Depreitere B, Fehlings MG, Kawahara N, Lee CS, Leung Y, Martin-Benlloch JA, Massicotte EM, Mazel C, Meyer B, Oner FC, Peul W, Quraishi N, Tokuhashi Y, Tomita K,...
Lancet Neurol. 2018 Nov 26;:
Badhiwala JH, Wilson JR, Fehlings MG
Cancer. 2018 Nov 29;:
Barzilai O, Versteeg AL, Sahgal A, Rhines LD, Bilsky MH, Sciubba DM, Schuster JM, Weber MH, Pal Varga P, Boriani S, Bettegowda C, Fehlings MG, Yamada Y, Clarke MJ, Arnold PM, Gokaslan ZL, Fisher CG, Laufer I, The Ao Spine Knowledge Forum Tumor

Pages


 

Head, Spinal Program, Toronto Western Hospital, UHN
McEwen Centre for Regenerative Medicine, UHN
Professor, Department of Surgery, University of Toronto
Vice Chair Research, Department of Surgery, University of Toronto
Co-Director, Spine Program, University of Toronto
Member, Institute of Medical Science, University of Toronto
McLaughlin Center in Molecular Medicine, University of Toronto